Pharmaceutical Growing demand for access to health care alongside advances in science and technology has led to heightened scrutiny of whether or not new medicines provide clinical, economic and patient value, writes Louise Parmenter, global head of operations, Epidemiology and Outcomes Research, Real-World and Late Phase Research, and Anke van Engen, senior consulting director, practice leader HTA Solutions at contract research organization Quintiles. 5 January 2015